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Using spoligotyping, we identiﬁ   ed 13 genotypes and 
17 orphan types among 160 Mycobacterium tuberculosis 
isolates from patients in Valle del Cauca, Colombia. The 
Beijing genotype represented 15.6% of the isolates and 
was correlated with multidrug-resistant tuberculosis, female 
sex of the patients, and residence in Buenaventura and may 
represent a new public health threat.
T
he state of Valle del Cauca in southwestern Colombia 
has a higher incidence of tuberculosis (TB) than the 
rest of the country (47 vs. 24 cases per 100,000 inhabitants 
per year) (1,2). One of its largest cities, Buenaventura, the 
main port of Colombia on the Paciﬁ  c Ocean, has multidrug-
resistant TB (MDR TB; resistance to at least isoniazid and 
rifampin) and an MDR TB rate of 6% (3).
Several genotypes of Mycobacterium tuberculosis 
have been reported in Colombia, but Latin American 
Mediterranean (LAM) and Haarlem (H) strains predominate 
(4,5). In Colombia, the Beijing genotype was ﬁ  rst detected 
in 1998 in 11 of 111 isolates from new and previously 
treated patients in Buenaventura (6). Further detection of 
this strain has been restricted to Valle del Cauca (www.ins.
gov.co/index.php?idcategoria=8304).
The Beijing genotype was originally reported in 
China in 1995 and is associated with higher virulence and 
resistance to antituberculosis drugs in many areas (7–10). 
Therefore, the Beijing genotype of M. tuberculosis is likely 
to have had a strong effect on development of the worldwide 
TB epidemic and the current emergence of MDR TB and 
extensively drug-resistant TB (XDR TB) (9).
South America has been relatively free of Beijing strains 
(10), and drug-resistance rates have not been extremely 
high in comparison with other regions. However, in this 
study, we report that the Beijing genotype is associated 
with MDR isolates in Colombia.
The Study
During January 2007–December 2008, health 
institutions in Valle del Cauca sent M. tuberculosis 
isolates to the Centro Internacional de Entrenamiento 
e Investigaciones Médicas in Cali, Colombia, for drug 
susceptibility testing. A total of 324 M. tuberculosis isolates 
from individual patients (new and previously treated) were 
subjected to ﬁ  rst-line drug susceptibility testing by using 
the agar proportion method with 7H10 medium.
In 2009, with approval from the Centro Internacional 
de Entrenamiento e Investigaciones Médicas Institutional 
Review Board, we thawed 160 (49%) of 324 isolates 
(76 MDR and 84 drug susceptible) and cultured them 
on Löwenstein-Jensen agar slants. Isolates with other 
susceptibility proﬁ  les were excluded from this analysis. 
Isolates were obtained from 9 municipalities in Valle del 
Cauca: Buenaventura (n = 113), Cali (n = 36), and 7 other 
locations (n = 11). Eighty-seven patients (54.4%) had new 
cases. There were more male patients (57.5%) than female 
patients, and the median age of all patients was 32 years 
(range 1–82 years).
DNA extraction was performed by using the 
hexadecyltrimethylammonium bromide method (11), 
and isolates were subjected to spoligotyping (12). 
Spoligopatterns obtained were analyzed independently by 
2 readers and compared with SpolDB4.0 (Pasteur Institute 
of Guadeloupe, Les Abymes, Guadeloupe) and MIRU-
VNTRplus (www.miru-vntrplus.org) to assign them to a 
known genotype family.
Statistical analysis was conducted by using Stata 
version 9.0 (StataCorp LP, College Station, TX, USA) 
and the Openepi (www.openepi.com). Odds ratios (ORs) 
and 95% conﬁ  dence intervals were calculated by using 
the Fisher exact test method. Chi-square test was used to 
determine statistical signiﬁ  cance.
Thirteen genotypes were identiﬁ   ed among the 
160 isolates: LAM9 (32; 20%), H1 (32; 20%), Beijing 
(25; 15.6%), T1 (9; 5.6%), U (9; 5.6%), LAM2 (6; 3.8%), 
LAM3 (5; 3.1%), LAM1 (4; 2.5%), X1 (4; 2.5%), H3 (4; 
2.5%), U (LAM30) (2; 1.3%), X3 (2; 1.3%), and LAM6 
(1; 0.6%). Orphan genotypes accounted for 25 (15.6%) 
isolates, and 12 of these isolates were grouped in 4 patterns 
(Table 1).
Overall, the LAM and H families were the most 
common among isolates evaluated, particularly among 
susceptible ones. H strains represented a homogeneous 
group and were distributed in 4 spoligo-international types 
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in 10 SITs (17, 20, 42, 64, 130, 162, 469, 545, 1711, and 
1803).
Three results were obtained regarding the Beijing 
genotype. First, a Beijing family strain (SIT 190) caused 
the largest cluster among the MDR isolates, comprising 24 
cases. The remaining Beijing strain (SIT 1) corresponded 
to a susceptible isolate from Buenaventura (Table 1). 
Second, the Beijing genotype showed a strong correlation 
with female patients and patients residing in Buenaventura 
(Table 2). Third, Beijing SIT 190 was found in 2 of 4 XDR 
TB isolates, as conﬁ  rmed in susceptibility testing by the 
Instituto de Salud Pública de Chile (Santiago, Chile). These 
2 isolates were found in 2 women, 16 and 24 years of age. 
The other 2 XDR TB isolates were an H strain and an 
orphan genotype strain.
Conclusions
Although our study used a convenience sample, 
it identiﬁ   ed a high frequency of Beijing strains among 
MDR TB isolates and showed an association between 
the Beijing genotype and MDR TB in Latin America. In 
Buenaventura, where a high rate of primary drug resistance 
has been observed (3,6), the Beijing genotype is associated 
with MDR TB and thus transmission. Moreover, given the 
limited number of MDR isolates tested, the emergence of 
Beijing strains in Colombia may already be much larger 
than what we observed.
In multiple areas worldwide, the Beijing genotype 
has been associated with young patients and active and 
recent transmission (8). In our study, the same tendency 
was observed, and this may suggest the emergence of this 
genotype family in Colombia.
The high frequency of the Beijing strain might be 
caused by bacteriologic factors, host factors, or both 
(8). Valle del Cauca has a high proportion of persons of 
African descent (27.2% according to the national census 
in 2005); especially in Buenaventura, where 23 of the 25 
Beijing isolates were found. Also, Buenaventura, which 
has >300,000 inhabitants, has a high TB incidence (72 
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Table 1. Frequency of genotypes by family in Mycobacterium tuberculosis isolates from Valle del Cauca, Colombia, 2007–2008* 
Family  No. (%) isolates 
Patient data 
M/F
No. with susceptible isolates/  
no. with MDR isolates 
No. with new treatment/ 
no. previously treated 
Beijing 25 (15.6) 9/16 1/24 13/11†
LAM1 4 (2.5) 4/0 4/0 4/0
LAM2 6 (3.8) 4/2 3/3 3/2†
LAM3 5 (3.1) 2/3 3/2 3/2
LAM6 1 (0.6) 1/0 1/0 0/1
LAM9 32 (20) 21/11 24/8 19/12†
H1 32 (20) 17/15 22/10 15/17
H3 4 (2.5) 2/2 4/0 4/0
T1 9 (5.6) 4/5 9/0 8/0†
U 9 (5.6) 6/3 2/7 3/6
U (LAM30) 2 (1.3) 2/0 2/0 1/1
X1 4 (2.5) 3/1 1/3 2/2
X3 2 (1.3) 2/0 2/0 2/0
Orphan1 1 (0.6) 0/1 1/0 1/0
Orphan2 2 (1.3) 0/2 0/2 1/1
Orphan3 1 (0.6) 0/1 1/0 1/0
Orphan4 2 (1.3) 1/1 0/2 2/0
Orphan5 1 (0.6) 1/0 0/1 0/1
Orphan6 1 (0.6) 0/1 0/1 1/0
Orphan7 1 (0.6) 1/0 0/1 0/1
Orphan8 1 (0.6) 0/1 0/1 1/0
Orphan9 1 (0.6) 0/1 0/1 0/1
Orphan10 1 (0.6) 1/0 0/1 0/1
Orphan11 1 (0.6) 1/0 0/1 0/1
Orphan12 6 (3.8) 5/1 0/6 2/4
Orphan13 1 (0.6) 1/0 1/0 1/0
Orphan14 1 (0.6) 1/0 0/1 0/1
Orphan15 1 (0.6) 1/0 1/0 1/0
Orphan16 1 (0.6) 1/0 1/0 0/0†
Orphan17 2 (1.3) 2/0 2/0 0/2
Total 160 (100) 93/67 84/76 87/68
*MDR, multidrug resistant. 
†Complete data were not available for 5 genotypes. MDR M. tuberculosis, Southwestern Colombia
cases/100,000 inhabitants/year) (13). Commercial and 
tourism activities and high population mobility in this city 
may contribute to dissemination of the Beijing genotype 
to other regions of Colombia. Two persons infected with 
the Beijing strain found in Cali, Colombia, in this study 
and a recently described 15-year-old person with MDR 
TB infected with a Beijing-like genotype, who died in 
Bogotá shortly after initiation of treatment, may represent 
preliminary evidence of the mentioned risk (14).
Our results differ from those of a report that described 
a low frequency of Beijing strains in Latin America and no 
association with drug resistance (10). However, Colombia 
might have recently become a port of entry for Beijing 
strains and this entry may have started earlier without being 
detected. Additional epidemiologic and clinical information 
is necessary to correlate our ﬁ  ndings with other factors, 
such as M. bovis BCG vaccination, ethnic group, disease 
severity, and outcome.
More discriminative typing methods such as 
mycobacterial interspersed repetitive unit–variable number 
tandem repeat analysis (15) or whole genome sequencing 
would enable typing to the strain level. This typing would 
shed light on epidemiologic links between the cases we 
reported and worldwide spread of the Beijing strain and 
on the location of these Beijing strains in a worldwide 
phylogenetic tree. Nevertheless, spoligotyping used in 
this study is sufﬁ   cient to conclude that drug-resistant 
Beijing strains have become a public health problem in 
Buenaventura, Colombia.
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